Transcranial Magnetic Stimulation (TMS) for Primary Progressive Apraxia of Speech (PPAOS)

Not Applicable

Terminated

• Conditions: Apraxia Speech
• Interventions: Device: Transcranial Magnetic Stimulation (TMS)

• Registration Number: NCT03028324
• Lead Sponsor: University of Miami

Brief Summary

The purpose of this study is to assess the influence of transcranial magnetic stimulation (TMS) on speech performance in individuals with primary progressive apraxia of speech.

Detailed Description

Apraxia of speech (AOS) is a motor speech disorder affecting the programming of motor speech production. It is characterized by the impaired ability to coordinate the sequential, articulatory movements necessary to produce speech sound. It can result from insult to the brain, such as in stroke, or as the presenting sign/symptom of another neurodegenerative disease.

TMS is a neurostimulation technique which has been shown to modulate cortical excitability in a non-invasive manner, and has been associated with positive outcomes in a variety of neurological and psychological disorders.There is evidence to support the role of TMS in individuals with primary progressive aphasias. In addition, there is a a case report suggesting an improvement in speech following TMS in an individual with primary progressive AOS. This study is being undertaken to further examine the role of TMS in primary progressive AOS.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2017-01-16
• Study First Submitted QC: 2017-01-20
• Study First Posted: 2017-01-23
• Study Start: 2017-08-09
• Primary Completion: 2018-11-13
• Study Completion: 2018-11-13
• Results First Submitted: 2020-02-24
• Status Verified: 2020-05
• Results First Submitted QC: 2020-05-22
• Last Update Submitted: 2020-05-22
• Results First Posted: 2020-05-26
• Last Update Posted: 2020-05-26

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 4

Inclusion Criteria

• Adults ages 18 and above who are able to consent
• Diagnosis of primary progressive apraxia of speech based on neurological evaluation

Read More

Exclusion Criteria

• Any uncontrolled medical condition expected to limit life expectancy or interfere with participation in the trial (i.e. unstable cancer, severe depression or anxiety by DSM-IV criteria)

• Abnormal stress test, as determined by the treating physician (unless cardiology clearance provided)

• Active substance abuse or alcohol dependence

• Uncorrected vision or hearing deficits that would preclude administration of the cognitive measures

• Unwilling or unable to provide written informed consent

• History of fainting spells of unknown or undetermined etiology that might constitute seizures

• History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG or family history of treatment resistant epilepsy

• No medication is an absolute exclusion from TMS. Medications will be reviewed by the responsible MD and a decision about inclusion will be made based on the following:

  • The subject's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination with other CNS active drugs.
  • The published TMS guidelines review medications to be considered with TMS

• Any metal in the brain, skull or elsewhere unless approved by the responsible MD

• Any medical devices (i.e. Cardiac pacemaker, deep brain stimulator, medication infusion pump, cochlear implant, vagal nerve stimulator) unless otherwise approved by the responsible MD

• Substance abuse or dependence within the past six months

• Absence of corticospinal functional integrity

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Transcranial Magnetic Stimulation (TMS)	Transcranial Magnetic Stimulation (TMS)	Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.

Primary Outcome Measures

Name	Time	Method
Change in Speech Performance	Baseline, 4 weeks	Apraxia of Speech Rating Scale has a total range from 0-64, with lower scores indicating lower impairment and higher scores indicating higher impairment.

Secondary Outcome Measures

Name	Time	Method
Change in Motor Cortex Excitability	Baseline, 4 weeks	Motor cortex excitability will be assessed with single-pulse TMS

Trial Locations

Locations (1)

University of Miami Miller School of Medicine; 🇺🇸 Miami, Florida, United States